Phenylketonuria clinical trials at UCLA
2 in progress, 1 open to eligible people
JNT-517 in Participants With Phenylketonuria (PKU)
open to eligible people ages 4 years and up
This Phase 3 study will evaluate the safety, effectiveness, tolerability, and how the body processes JNT-517 in children, adolescents, and adults with phenylketonuria. Participants will be randomly assigned to receive either JNT-517 or placebo during an initial 6-week treatment period. After this period, eligible participants will receive JNT-517 for an additional 46 weeks.
Los Angeles, California and other locations
Immune Modulation During Palynziq® Treatment in Adults (IMPALA)
Sorry, not currently recruiting here
Study 165-401 is a Phase 4, open-label study designed to examine the concomitant use of methotrexate (MTX) to suppress immune responses to Palynziq and improve tolerability and efficacy in adults with PKU.
Los Angeles, California and other locations
Our lead scientists for Phenylketonuria research studies include Nicola Longo.
Last updated: